REGENERATIVE MEDICINE FOR THE TREATMENT OF HEART DISEASE
Shortage of organs and rejection reactions are worldwide challenges in organ transplantation
An improved system to generate mature human cardiomyocytes for 3D culture & cardiopatch
- An effective tool for drug screening in heart disease models
- Regenerative medicine for the treatment of heart disease
- A potential biological patch for post-infarct scars
- A new technology for the generation of mature human cardiomyocytes
One application for this technology is the in vitro use of a cardiac construct for the screening or evaluation of compounds for cardioprotective or cardiotoxic properties, and for cardiac disease modeling.
The present invention also represents a new therapeutic option for patients with acute myocardial infarction, which present post-infarct scars. CTE products could be implanted in damaged myocardium and shrink simultaneously with healthy tissue. At that moment, an improvement in contractile strength would occur, as well as in patient’s life quality and life expectancy.
Preclinical studies have been completed, demonstrating the efficacy in reproducing cardiomyocytes. Future work: CTE products, generated under GMP conditions and following AEMPS policies, which consist of 2 elements: decellularized scaffolds (biocompatible and highly similar to native myocardium) and cellular component (Wharton's Jelly-derived Mesenchymal Stem Cells or iPS).
Preclinical studies have to be completed, demonstrating the security and efficacy of CTE products (in vitro and in vivo - mice and pork). It is expected to reduce infarct size and to improve the functionality. A pilot study is being prepared to be performed in patients. IP status: Patent application in June 2018.